Category Archives: Drug Side Effects

Public release date: 26-Feb-2013 [ | E-mail | Share ] Contact: Emma Mason wordmason@mac.com European Society of Cardiology The largest randomised study of the vitamin niacin in patients with occlusive arterial disease (narrowing of the arteries) has shown a significant increase in adverse side-effects when it is combined with statin treatment. Results from the HPS2-THRIVE study (Heart Protection Study 2 Treatment of HDL to Reduce the Incidence of Vascular Events), including the reasons patients stopped the study treatment, are published online today (Wednesday) in the European Heart Journal [1]. Niacin has been used for decades to help increase levels of "good" HDL cholesterol and to decrease levels of "bad" LDL cholesterol and triglycerides (fats) in the blood in people at risk of cardiovascular problems such as heart disease and stroke. However, it has a number of side-effects including flushing of the skin. Another drug, laropiprant, can reduce the incidence of flushing by blocking the prostaglandin D2 receptor that is involved in the process. Therefore, the HPS2-THRIVE study investigated whether combining extended-release niacin with laropiprant (ERN/LRPT), given in addition to an LDL cholesterol-lowering statin, simvastatin, could reduce the risk of cardiovascular problems in people at high risk due to existing occlusive … Continue reading →

Dallas, TX (PRWEB) February 25, 2013 The prescription drug resource center DrugRisk.com is alerting those patients whove taken the diabetes drug Actos of updated legal news on the site showing trial will commence this week in the first of thousands of lawsuits filed over bladder cancer. The goal of DrugRisk is to improve patient safety through education, including the latest drug warnings, recalls, studies and litigation news. By following the cases of others, patients can discuss options with their doctor and decide if they need legal advice, explains DrugRisk representative Ryan Mayer. The resource center has added Actos warnings by both the FDA* and European Medicines Agency** who indicated that long-term use of the drug may be associated with an increased risk of bladder cancer. The drug has also been banned in France and Germany.*** In DrugRisk legal news, more than 1,200 patients have filed an Actos lawsuit against drug maker Takeda Pharmaceuticals in a special multi-district federal court in Louisiana. The case is known as In Re: Actos Products Liability Litigation, MDL 2299, U.S. District Court, Western District of Louisiana (Lafayette). Now, the resource center is reporting that another group of Actos cases are set to kick off this … Continue reading →

Dallas, TX (PRWEB) February 25, 2013 The prescription drug resource center DrugRisk.com is alerting patients taking the birth control drugs Yaz or Yasmin of new information to be added to the site showing the latest Yaz settlement figures from Bayer. The mission of DrugRisk is to improve patient safety through education. This includes the latest warnings, recalls, studies and litigation news related to popular drugs like Yaz. Informed users can discuss options with their doctor and decide if they need legal advice, explains DrugRisk representative Ryan Mayer. The resource center had previously added studies from the British Medical Journal and U.S. FDA which warned birth control pills containing the hormone drospirenone, like Yaz and Yasmin, can increase the risk of blood clots, DVT and pulmonary embolism by as much as 74%.* DrugRisk has also uncovered information from Bayer, the maker of the drugs, indicating more than 12,000 women taking Yaz or Yasmin have filed a lawsuit over side effects like DVT and pulmonary embolism.** Due to the number of patients filing a Yaz lawsuit, cases were consolidated to a special federal Multi-District Litigation court in Illinois. The formal case is known as Yasmin and Yaz (Drospirenone) Marketing, Sales Practices and … Continue reading →

Orlando, FL (PRWEB) February 25, 2013 The prescription drug resource center DrugRisk.com is alerting patients taking the popular blood thinner Pradaxa of updated legal news information added to the site showing the federal court overseeing Pradaxa bleeding lawsuits has scheduled a new hearing for next month. DrugRisks mission is to improve the patient safety by providing the latest drug warnings, recalls, studies and litigation news. Patients informed of drug news can discuss side effect options with their doctor and decide if they need legal advice, explains DrugRisk representative Ryan Mayer. The resource center contains information from health organizations showing experts have differing opinions about the safety of Pradaxa. The FDA recently updated an advisory to indicate the drug carries the same risks as warfarin.* However, the American College of Cardiology has warned Pradaxa can significantly increase the risk of bleeding complications compared to warfarin.** DrugRisk has also obtained a report from the Institute for Safe Medication Practices ranking anticoagulants like Pradaxa among the highest risk outpatient drugs. In reviewing adverse event reports of hemorrhaging submitted to the FDA, the institute found bleeding from Pradaxa almost 5 times as likely to result in death than with warfarin.*** Due to the number … Continue reading →

Los Angeles, CA (PRWEB) February 26, 2013 The prescription drug resource center DrugRisk.com is alerting patients taking the popular blood thinner Pradaxa of updated information added to the site showing the maker of Pradaxa, Boehringer Ingelheim, has funded a study which disputes prior warnings over bleeding risks. DrugRisks mission is to improve the patient safety by providing the latest drug warnings, recalls, studies and litigation news. In the case of research, it is important for patients to know whether it is independent or funded by drug makers with a financial stake in the outcome, explains DrugRisk representative Ryan Mayer. The resource center contains information from health organizations showing experts have differing opinions about the safety of Pradaxa. The FDA recently updated an advisory to indicate the drug carries the same risks as warfarin.* However, the American College of Cardiology has warned Pradaxa can significantly increase the risk of bleeding complications compared to warfarin.** DrugRisk has also obtained a recent study from the Institute for Safe Medication Practices which again ranks blood thinners like Pradaxa among the most dangerous drugs. In reviewing nearly 18,000 adverse events reported to the FDA, the institute found those patients with bleeding from Pradaxa are nearly … Continue reading →

Dallas, TX (PRWEB) February 26, 2013 The birth control safety advocates at DrugRisk.com are alerting those who have taken the oral contraceptives Yaz or Yasmin that new information will be added this week showing how many Yaz lawsuits Bayer has settled, how much they have paid, and what type of cases they are settling. DrugRisks goal is to improve consumer safety through education of the latest drug warnings, recalls, studies and litigation news. We receive calls every day from patients concerned over blood clot side effects and whether Bayer is still compensating victims, explains DrugRisk representative Ryan Mayer. The resource center contains studies from the British Medical Journal and FDA which warned birth control pills containing the hormone drospirenone, like Yaz and Yasmin, can increase the risk of blood clots, DVT and pulmonary embolism by as much as 74%.* In previous financial information uncovered by DrugRisk, Bayer admitted more than 12,000 women taking Yaz or Yasmin had filed a Yaz lawsuit over side effects like DVT and pulmonary embolism.** Due to the number of patients filing a claim, they were consolidated to a special federal Multi-District Litigation court in Illinois. The case is known as Yasmin and Yaz (Drospirenone) Marketing, … Continue reading →

Quick links to other pages on this site | Still can't find it? see Site Index WASHINGTON The Food and Drug Administration has approved a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones. The drug Kadcyla from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together. The chemical keeps the cocktail intact until it binds to a cancer cell, delivering a potent dose of anti-tumor poison. Cancer researchers said the drug is an important step forward because it delivers more medication while reducing the unpleasant side effects of chemotherapy. This antibody goes seeking out the tumor cells, gets internalized and then explodes them from within. So its very kind and gentle on the patients; theres no hair loss, no nausea, no vomiting, said Dr. Melody Cobleigh of Rush University Medical Center. Its a revolutionary way of treating cancer. Cobleigh helped conduct the key studies of the drug at the Chicago facility. The FDA approved the new treatment for about 20 percent of breast cancer patients with a form of the disease that is typically more aggressive and less responsive to hormone therapy. These patients have tumors … Continue reading →

J. Robert Davis - Personal Injury Attorney in San Antonio The Law Offices of J. Robert Davis, PC is a San Antonio personal injury law firm. We provide experienced attorneys to fight for our clients injured by truck car accidents, boating motorcycle accidents, injuries due to drugs medical devices and other personal injuries. Practice Areas Motor vehicle accidents Personal injury Workplace injury Drug side effects Medical devices Defective products By: Doug Mansfield … Continue reading →

Mainstream Media and Drugs Are you aware of what is happening with drugs in this country and the side effects they have? Unfortunately many of us do not know the damaging effects of certain drugs because the FDA is not requiring these companies to put the warnings on the their labels. By: DivineSpine … Continue reading →

WASHINGTON (AP) The Food and Drug Administration has approved a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones. The drug Kadcyla from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together. The chemical keeps the cocktail intact until it binds to a cancer cell, delivering a potent dose of anti-tumor poison. Cancer researchers say the drug is an important step forward because it delivers more medication while reducing the unpleasant side effects of chemotherapy. "This antibody goes seeking out the tumor cells, gets internalized and then explodes them from within. So it's very kind and gentle on the patients there's no hair loss, no nausea, no vomiting," said Dr. Melody Cobleigh of Rush University Medical Center. "It's a revolutionary way of treating cancer." Cobleigh helped conduct the key studies of the drug at the Chicago facility. The FDA approved the new treatment for about 20 percent of breast cancer patients with a form of the disease that is typically more aggressive and less responsive to hormone therapy. These patients have tumors that overproduce a protein known as HER-2. Breast cancer is the second most deadly form … Continue reading →